Michelle Phung

Michelle Phung

Auto-generated profile, based on publicly available information

Michelle Phung

Department of Dermatology, Stanford University, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in NEJM AI
Verified
Journal Article
Closed access
ACAlbert S. Chiou
Albert S. Chiou
JOJesutofunmi A. Omiye
Jesutofunmi A. Omiye
HGHaiwen Gui
Haiwen Gui
SSSusan M. Swetter
Susan M. Swetter
JKJustin M. Ko
Justin M. Ko
RNRoberto A. Novoa
Roberto A. Novoa

21 June 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MPMichelle Phung
Michelle Phung
VMVijaytha Muralidharan
Vijaytha Muralidharan
VRVeronica Rotemberg
Veronica Rotemberg
RNRoberto Andres Novoa
Roberto Andres Novoa
ACAlbert Sean Chiou
Albert Sean Chiou
RDRoxana Daneshjou
Roxana Daneshjou

27 June 2022 in Skin Health and Disease
Verified
Journal Article
Open access
PTPavin Trinh
Pavin Trinh
KYKiana Yekrang
Kiana Yekrang
MPMichelle Phung
Michelle Phung
SPSilvina Pugliese
Silvina Pugliese
ACAnne Lynn S. Chang
Anne Lynn S. Chang
KSKavita Y. Sarin
Kavita Y. Sarin
Background: Elderly patients in senior communities faced high barriers to care during the COVID-19 pandemic, including increased vulnerability to COVID-19, long quarantines for clinic visits, and difficulties with telemedicine adoption. Objective: To pilot a new model of dermatologic care to overcome barriers for senior living communities during the COVID-19 pandemic and assess patient satisfaction. Methods: From 16 November 2020 to 9 July 2021, this quality improvement programme combined in-residence full body imaging with real-time outlier lesion identification and virtual teledermatology. Residents from the Sequoias Portola Valley Senior Living Retirement Community (Portola Valley, California) voluntarily enroled in the Stanford Skin Scan Programme. Non-physician clinical staff with a recent negative COVID-19 test travelled on-site to obtain in-residence full body photographs using a mobile app-based system on an iPad called SkinIO that leverages deep learning to analyse patient images and suggest suspicious, outlier lesions for dermoscopic photos. A single dermatologist reviewed photographs with the patient and provided recommendations via a video visit. Objective measures included follow-up course and number of skin cancers detected. Subjective findings were obtained through patient experience surveys. Results: Twenty-seven individuals participated, three skin cancers were identified, with 11 individuals scheduled for a follow up in-person visit and four individuals starting home treatment. Overall, 88% of patients were satisfied with the Skin Scan programme, with 77% likely to recommend the programme to others. 92% of patients agreed that the Skin Scan photographs were representative of their skin. In the context of the COVID-19 pandemic, 100% of patients felt the process was safer or comparable to an in-person visit. Despite overall appreciation for the programme, 31% of patients reported that they would prefer to see dermatologist in-person after the pandemic. Conclusions: This programme offers a framework for how a hybrid skin scan programme may provide high utility for individuals with barriers to accessing in-person clinics.

16 March 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
JGJorge R. Georgakopoulos
Jorge R. Georgakopoulos
KLKaitlyn Lam
Kaitlyn Lam
VSVijay K. Sandhu
Vijay K. Sandhu
AIArvin Ighani
Arvin Ighani
MPMichelle Phung
Michelle Phung
JYJensen Yeung
Jensen Yeung

30 March 2022 in JMIR Formative Research
Verified
Journal Article
Open access
CSCharlene Soobiah
Charlene Soobiah
MPMichelle Phung
Michelle Phung
MTMina Tadrous
Mina Tadrous
TJTrevor Jamieson
Trevor Jamieson
RBR Sacha Bhatia
R Sacha Bhatia
LDLaura Desveaux
Laura Desveaux
Background: Centralized drug repositories can reduce adverse events and inappropriate prescriptions by enabling access to dispensed medication data at the point of care; however, how they achieve this goal is largely unknown. Objective: This study aims to understand the perceived clinical value; the barriers to and enablers of adoption; and the clinician groups for which a provincial, centralized drug repository may provide the most benefit. Methods: A mixed methods approach, including a web-based survey and semistructured interviews, was used. Participants were clinicians (eg, nurses, physicians, and pharmacists) in Ontario who were eligible to use the digital health drug repository (DHDR), irrespective of actual use. Survey data were ranked on a 7-point adjectival scale and analyzed using descriptive statistics, and interviews were analyzed using qualitative descriptions. Results: Of the 161 survey respondents, only 40 (24.8%) actively used the DHDR. Perceptions of the utility of the DHDR were neutral (mean scores ranged from 4.11 to 4.76). Of the 75.2% (121/161) who did not use the DHDR, 97.5% (118/121) rated access to medication information (eg, dose, strength, and frequency) as important. Reasons for not using the DHDR included the cumbersome access process and the perception that available data were incomplete or inaccurate. Of the 33 interviews completed, 26 (79%) were active DHDR users. The DHDR was a satisfactory source of secondary information; however, the absence of medication instructions and prescribed medications (which were not dispensed) limited its ability to provide a comprehensive profile to meaningfully support clinical decision-making. Conclusions: Digital drug repositories must be adjusted to align with the clinician’s needs to provide value. Ensuring integration with point-of-care systems, comprehensive clinical data, and streamlined onboarding processes would optimize clinically meaningful use. The electronic provision of accessible drug information to providers across health care settings has the potential to improve efficiency and reduce medication errors.

14 January 2021 in JMIR Preprints
Verified
Preprint
Open access
CSCharlene Soobiah
Charlene Soobiah
MPMichelle Phung
Michelle Phung
MTMina Tadrous
Mina Tadrous
TJTrevor Jamieson
Trevor Jamieson
RBR Sacha Bhatia
R Sacha Bhatia
LDLaura Desveaux
Laura Desveaux
BACKGROUND Centralized drug repositories can reduce adverse events and inappropriate prescriptions by enabling access to dispensed medication data at the point of care; however, how they achieve this goal is largely unknown. OBJECTIVE This study aims to understand the perceived clinical value; the barriers to and enablers of adoption; and the clinician groups for which a provincial, centralized drug repository may provide the most benefit. METHODS A mixed methods approach, including a web-based survey and semistructured interviews, was used. Participants were clinicians (eg, nurses, physicians, and pharmacists) in Ontario who were eligible to use the digital health drug repository (DHDR), irrespective of actual use. Survey data were ranked on a 7-point adjectival scale and analyzed using descriptive statistics, and interviews were analyzed using qualitative descriptions. RESULTS Of the 161 survey respondents, only 40 (24.8%) actively used the DHDR. Perceptions of the utility of the DHDR were neutral (mean scores ranged from 4.11 to 4.76). Of the 75.2% (121/161) who did not use the DHDR, 97.5% (118/121) rated access to medication information (eg, dose, strength, and frequency) as important. Reasons for not using the DHDR included the cumbersome access process and the perception that available data were incomplete or inaccurate. Of the 33 interviews completed, 26 (79%) were active DHDR users. The DHDR was a satisfactory source of secondary information; however, the absence of medication instructions and prescribed medications (which were not dispensed) limited its ability to provide a comprehensive profile to meaningfully support clinical decision-making. CONCLUSIONS Digital drug repositories must be adjusted to align with the clinician’s needs to provide value. Ensuring integration with point-of-care systems, comprehensive clinical data, and streamlined onboarding processes would optimize clinically meaningful use. The electronic provision of accessible drug information to providers across health care settings has the potential to improve efficiency and reduce medication errors.